

# Brian Ruffell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4237526/publications.pdf>

Version: 2024-02-01

48  
papers

10,579  
citations

136950  
32  
h-index

243625  
44  
g-index

52  
all docs

52  
docs citations

52  
times ranked

16630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. <i>Cancer Discovery</i> , 2011, 1, 54-67.	9.4	1,486
2	Macrophages as regulators of tumour immunity and immunotherapy. <i>Nature Reviews Immunology</i> , 2019, 19, 369-382.	22.7	1,365
3	Macrophages and Therapeutic Resistance in Cancer. <i>Cancer Cell</i> , 2015, 27, 462-472.	16.8	1,130
4	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. <i>Cancer Cell</i> , 2014, 26, 623-637.	16.8	751
5	Differential macrophage programming in the tumor microenvironment. <i>Trends in Immunology</i> , 2012, 33, 119-126.	6.8	721
6	Dendritic Cells and Cancer Immunity. <i>Trends in Immunology</i> , 2016, 37, 855-865.	6.8	624
7	Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. <i>Cancer Discovery</i> , 2016, 6, 270-285.	9.4	408
8	Leukocyte composition of human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2796-2801.	7.1	393
9	CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 <sup>+</sup> T cells. <i>Oncotarget</i> , 2013, 2, e26968.	4.6	311
10	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. <i>Cancer Cell</i> , 2018, 33, 60-74.e6.	16.8	270
11	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4119-4132.	7.0	266
12	MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles. <i>Clinical Cancer Research</i> , 2011, 17, 5695-5704.	7.0	262
13	Dendritic Cells and Their Role in Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 924.	4.8	253
14	B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas. <i>Cancer Cell</i> , 2014, 25, 809-821.	16.8	245
15	Lymphocytes in cancer development: Polarization towards pro-tumor immunity. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 3-10.	7.2	198
16	TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 518-525.	3.4	197
17	Role of CD44 and Hyaluronan in Neutrophil Recruitment. <i>Journal of Immunology</i> , 2004, 173, 7594-7601.	0.8	178
18	Inflammation, ROS, and Mutagenesis. <i>Cancer Cell</i> , 2017, 32, 727-729.	16.8	164

#	ARTICLE	IF	CITATIONS
19	CD44 and its Role in Inflammation and Inflammatory Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2009, 8, 208-220.	1.8	163
20	Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. <i>Nature Materials</i> , 2021, 20, 548-559.	27.5	125
21	Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma. <i>Journal of Immunology</i> , 2013, 191, 2009-2017.	0.8	116
22	The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. <i>Immunity</i> , 2021, 54, 1154-1167.e7.	14.3	109
23	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. <i>Immunity</i> , 2020, 52, 668-682.e7.	14.3	107
24	Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. <i>British Journal of Cancer</i> , 2019, 121, 556-566.	6.4	86
25	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. <i>Oncotarget</i> , 2016, 7, 82482-82492.	1.8	78
26	Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. <i>Genes and Development</i> , 2013, 27, 2086-2098.	5.9	74
27	Hyaluronan Induces Cell Death in Activated T Cells through CD44. <i>Journal of Immunology</i> , 2008, 181, 7044-7054.	0.8	58
28	Mucosal Immunity in the Female Murine Mammary Gland. <i>Journal of Immunology</i> , 2018, 201, 734-746.	0.8	58
29	The Immune Microenvironment and Cancer Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037424.	6.2	57
30	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 495-508.	2.5	52
31	Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 5477-5490.	0.9	48
32	Differential Use of Chondroitin Sulfate to Regulate Hyaluronan Binding by Receptor CD44 in Inflammatory and Interleukin 4-activated Macrophages. <i>Journal of Biological Chemistry</i> , 2011, 286, 19179-19190.	3.4	47
33	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 5034-5047.	0.9	37
34	Chondroitin sulfate addition to CD44H negatively regulates hyaluronan binding. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 306-312.	2.1	17
35	Histamine restricts cancer: nothing to sneeze at. <i>Nature Medicine</i> , 2011, 17, 43-44.	30.7	15
36	Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 283-293.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Immune Regulation of the Metastatic Process. <i>Advances in Cancer Research</i> , 2016, 132, 139-163.	5.0	14
38	Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 535-537.	16.8	14
39	Monocytes promote liver carcinogenesis in an oncogene-specific manner. <i>Journal of Hepatology</i> , 2016, 64, 881-890.	3.7	13
40	TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8 <sup>+</sup> T cell and XCR1 <sup>+</sup> dendritic cell spatial co-localization. , 2022, 10, e003571.		13
41	Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 120-126.	1.4	10
42	Metabolism in tumor-associated macrophages. <i>International Review of Cell and Molecular Biology</i> , 2022, 367, 65-100.	3.2	10
43	moDCs, Less Problems. <i>Immunity</i> , 2018, 48, 6-8.	14.3	8
44	Cavity macrophages stop anti-tumor T <sup>H</sup> cells. <i>Cancer Cell</i> , 2021, 39, 900-902.	16.8	2
45	Tipping the Balancing ACT. <i>Cancer Cell</i> , 2016, 30, 367-368.	16.8	1
46	Some DCs Are "Better". <i>Immunity</i> , 2013, 38, 626-628.	14.3	0
47	Reducing interferon $\gamma$ in stem cells. <i>Nature Cell Biology</i> , 2017, 19, 597-599.	10.3	0
48	Detection of exogenous DNA uptake by murine dendritic cells. <i>STAR Protocols</i> , 2022, 3, 101464.	1.2	0